newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement t